← Back to all trials
Completed
NCT01046487
Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate
Conditions: Cancer
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE1
Enrollment: 26
Sponsor: Centre Oscar Lambret
Location: Institut Bergonié Bordeaux
Summary
The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).
Eligibility Criteria
Inclusion Criteria:
* Rare tumor
* metastatic disease or locally advanced disease, inoperable, with no standard treatment
* At least 28 days since the prior treatment
* Measurable disease with at least one measurable lesion
Exclusion Criteria:
* Medullary insufficiency
* Cystitis, haemorrhagic cystitis
* Hepatic porphyria
Source: ClinicalTrials.gov (NCT01046487). StuddyBuddy aggregates publicly available trial information.
